Unoprostone

Unoprostone
Clinical data
Trade namesRescula
AHFS/Drugs.comMicromedex Detailed Consumer Information
Routes of
administration		Topical (eye drops)
ATC code
Legal status
Legal status
  • US: Discontinued
Pharmacokinetic data
Elimination half-life14 min
ExcretionRenal
Identifiers
IUPAC name
  • (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)
    cyclopentyl]hept-5-enoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.227.145
Edit this at Wikidata
Chemical and physical data
FormulaC22H38O5
Molar mass382.541 g·mol−1
3D model (JSmol)
SMILES
  • O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CCC(=O)CCCCCCC
InChI
  • InChI=1S/C22H38O5/c1-2-3-4-5-8-11-17(23)14-15-19-18(20(24)16-21(19)25)12-9-6-7-10-13-22(26)27/h6,9,18-21,24-25H,2-5,7-8,10-16H2,1H3,(H,26,27)/b9-6-/t18-,19-,20+,21-/m1/s1 ☒N
  • Key:TVHAZVBUYQMHBC-SNHXEXRGSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Unoprostone (INN) is a prostaglandin analogue. Its isopropyl ester, unoprostone isopropyl, was marketed under the trade name Rescula for the management of open-angle glaucoma and ocular hypertension.[1][2]

It was approved by the Food and Drug Administration in 2000.[3]

In 2009, Sucampo Pharmaceuticals acquired the rights to the drug in the U.S. and Canada.[4]

In 2015, the drug was discontinued in the U.S.

References

  1. ↑ Micromedex Detailed Consumer Information
  2. ↑ Fung DS, Whitson JT (2014). "An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy". Clinical Ophthalmology. Auckland, N.Z. 8: 543–54. doi:10.2147/OPTH.S41562. PMC 3958522. PMID 24648719.
  3. ↑ "Drug Approval Package". Food and Drug Administration.
  4. ↑ "Sucampo Pharmaceuticals, Inc. Acquires Rights to Rescula for U.S. and Canada" (Press release). Business Wire. April 24, 2009.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.